ABSTRAm. Antithrombin 111, a major inhibitor of activated coagulation factors has low immunologic levels in the human infant. The objective of this study was to deermine if the antithrombin 111 molecule is fully functional in sick premature infants. The populations studied included: adult controls (n = 20), full term healthy infants (n = 18), sick premature infants on day 1 (n = 16) and at >7 days of age (n = lo), and infants with disseminated intravascular coagulation (n = 11). This was diagnosed in the presence of prolonged screening tests, decreased levels of fibrinogen, and platelets along with elevated fibrin degradation products. Plasma antithrombin 111 levels were measured biologically (chromogenic substrate S2238) and immunologically (radialimmunodiffusion), and expressed as a percent of adult pooled plasma. Crossed immunoelectrophoresis were performed in the presence and absence of heparin. The antithrombin 111 biologic/immunologic ratios for adults, healthy full term infants, and sick premature infants on day 1 of life were all near unity. In contrast sick premature infants beyond the 1st wk of life and infants with disseminated intravascular coagulation had lower biologic activity compared to immunologic (B/I = 0.77 f 0.28, 0.78 f 0.17, p < 0.01), respectively. In all groups, the antithrombin 111 molecule was normal on crossed immunoelectrophoresis except for one infant with disseminated intravascular coagulation. Sick premature infants may acquire a dysfunctional antithrombin 111 molecule in the postnatal period. (Pediatr Res 19: 237-239, 1985) Abbreviations AT-111, antithrombin 111 RDS, respiratory distress syndrome BPD, bronchopulmonary dysplasia DIC, disseminated intravascular coagulation CIE, cross-immunoelectrophoresis APTT, activated partial thromboplastin time PT, prothrombin time TcT, thrombin clotting time EACA, €-amino caproic acid Normal hemostasis depends on a delicate balance between the procoagulant and fibrinolytic systems and their respective inhibitors. AT-111, the major inhibitor for the coagulation system
inhibits factors XIIa, XIa, IXa, Xa, plasmin, and thrombin (5) . Healthy premature and full term infants have low levels of a normally functioning AT-I11 molecule at birth (30-50% of adult values) (3, 7, 13, 16, 22, 35) but do not develop spontaneous thrombosis as do adults with similar inherited low levels of AT-111. The infants with thrombotic complications have other underlying disorders such as RDS, BPD, and DIC which may in turn be associated with even lower levels of AT-I11 (2, 16, 26) . The objective of this study was to determine if the AT-I11 molecule functions normally in these sick premature infants as conceivably a dysfunctional molecule would increase the risk of abnormal thrombosis.
MATERIALS AND METHODS
Study Population. Premature infants admitted to McMaster University Medical Center who had coagulation screens performed for clinical indications were eligible for the study. Sick premature infants without DIC on day 1 (n = 16), > day 7 (n = lo), and infants with DIC within the 1st wk of life (n = 1 1) were studied. DIC was diagnosed in the presence of prolonged screening tests (PT, APTT), fibrinogen levels below 1.2 g/liter and elevated fibrin-related antigen. The infant's gestional age was determined according to the Dubowitz scoring method (12) . No infants received fresh-frozen plasma within the 72 h prior to the study sample and all received 1 mg of vitamin K intramuscularly on delivery. Cord blood samples were obtained from 18 healthy full term infants (37-42 wk gestation). In addition 20 healthy adults were studied. Informed consent was not obtained for the infants as cord samples were used in the full term infants and unused plasma samples from coagulation screens ordered for clinical indications were saved from the sick premature infants. Pertinent clinical information was obtained from the charts.
Coagulation tests. Blood samples (1 ml) were obtained from newly placed nonheparinized umbilical lines or from a peripheral vein, and placed in polypropylene tubes containing 0.13 M sodium citrate and 0.1 M (EACA (1 part citrate-EACA to 9 parts blood). Cord blood was drawn immediately at birth from the umbilical cord vein and treated in an identical manner. Platelet-poor plasma was stored in polypropylene tubes at -70" C until assaying. Assays on all samples were performed in a blind manner at McMaster University Health Sciences Centre. The following tests were performed: APTT (6), PT (6), TcT, fibrinogen (1 l), and fibrin-related antigen (Thrombo Wellcot). The immunologic concentration of AT-111 was determined by radial immunodiffusion as previously described (17) using commercially available antibodies (Atlantic Antibodies, Maynard Scientific, Mississauga, Ontario). The biologic levels of AT-I11 were determined by the ability to inhibit thrombin using the chromogenic substrate S-2238 (3 1) in the presence of heparin. CIE was achieved by the two dimensional immunoelectrophoresis technique of Laurel1 (1 8) ml of heparin in the first electrophoresis and 1 % AT-111 antiserum in the second. CIE was also performed in the absence of heparin in the first step and all control samples were diluted to the same antigenic concentration as the infants samples. Antithrombin activities and antigen levels are expressed as percent of a normal pooled plasma.
Results are expressed as means -+ SD. Differences between means comparing immunologic to biologic samples were analyzed by Student's paired two-tailed t test. p values below 0.05 were considered to be significant.
RESULTS
Twenty normal adults, 18 healthy full term infants, and 37 sick infants admitted to the McMaster University Health Sciences Centre were studied. The infants samples were selected prior to AT-111 determination to represent three groups: full term and premature infants with DIC (n = 1 I), premature infants on day 1 of life (n = 16), and premature infants > 7 days of age (n = 10). No infant was present in more than one group. The premature infants on both day 1 and 7 had a similar incidence of RDS (90%), and birth asphyxia (50%). All premature infants were examined for the presence of DIC. Sick premature infants on day 1 and > day 7 had normal coagulation profiles for their age while the infants with DIC had each of the abnormalities previously defined (Table 1) . Their gestational age, birth weight, and apgar scores are given in Table 2 . The infants with DIC had lower birth weights and lower apgar scores at birth than the other two groups. Twelve infants died and autopsies were performed on six. Large vessel thrombosis were noted for three, one infant with DIC and two > 7 days of age.
Equal levels of AT-I11 antigen and activity were measured for all adult controls, all healthy full term infants, and the majority of sick premature infants (12/16) on day 1 of life ( Table 3) . It is Fig. 1 . CIE in the presence of heparin for an adult (upper) and for an infant with DIC (lower). The adult sample has been diluted to equal the antigen concentration of the infant sample. The latter shows an additional slow moving peak in the first dimension which shares identity with the normally present peak.
of some interest that four sick premature infants on day 1 had an AT-111 B/I ratio < 0.6. The CIE were normal in the presence or absence of heparin for these groups.
Sick premature infants > day 7 and infants with DIC had lower biologic levels compared to immunologic levels (p c 0.0 1) ( Table 2) . Their CIE were also normal in the presence or absence of heparin except for one full term infant with DIC secondary to persistent severe acidosis. For this infant the CIE showed a slower migrating peak in the second dimension which shared identity with the peak normally present (Fig. 1) . Although two peaks are usually observed in the presence of heparin, none of the other infants or the diluted controls had the normally present smaller slower migrating peak, presumably because of the very low antigen concentration of these samples. Other published CIE in infants were also missing the smaller slower migrating peak (4).
DISCUSSION
AT-111 levels are normally low in the newborn and are dependent on a number of perinatal factors. Levels of AT-111 increase with increasing gestational age and postnatal age in healthy infants achieving values in the lower adult range as early as at 1 wk of age (3, 16) . AT-111 from both premature and full term cord blood has been isolated and is identical to AT-I11 from adults with respect to a variety of functional and immunologic properties thus excluding the possibility of a fetal form of AT-111 (16, 21) . This study confirms those reports; however, we observed a dysfunctional AT-111 molecule later in the postnatal period in a select population of sick premature infants. Previously infants with RDS and DIC have been reported to have lower levels of AT-111 compared to age-matched controls (3, 16, 26) ; however, AT-111 antigen and activity have not been compared for these infants.
Discrepancies between immunologic and biologic activities of AT-I11 may either be inherited or acquired. The hereditary thrombophilias associated with a dysfunctional antithrombin 111 molecule are a rare and heterogeneous group. For some cases (8, 23, 25, 32) a qualitative AT-111 deficiency was proposed based on the lack of correlation between AT-I11 antigen levels and AT-111 activity, similar to our observation. Others have noted an abnormal afinity for heparin and two-dimensional immunoelectrophoresis in the presence of heparin has revealed two peaks of AT-I11 (28, 30, 33, 36) . The dysfunctional AT-111 in this study appears to be an acquired, not an inherited, phenomena. It is therefore unlikely that an abnormal molecule is being produced as is the case for the hereditary thrombophilias.
In adults the same type of acquired dysfunctional AT-111 may occur in states of protease generation such as DIC, pancreatitis, and shock (14) . Radiolabeled studies show that AT-111 binds to thrombin to form complexes during in vivo thrombin generation (10) . AT-111-protease complexes have an abnormal mobility on CIE with the presence of a slower migrating peak (I, 19, 28) . We have observed this pattern in one full term infant with severe persistent DIC, however, it was not present in the other 10 infants with DIC. A second form of acquired AT-111 dysfunction could be due to acquired damage to the circulating AT-111 molecule. In support of this hypothesis discrepancies between immunologic and biologic activities have been reported for other coagulation proteins such as factors XI1 (2), prekallikrein (15) , and a , antitrypsin (9) in the sick neonate.
Thrombotic complications occur in the newborn infant, although the precise incidence is unknown (4, 24, 34) . The majority of infants who develop thrombotic complications are premature infants with RDS, some of whom also have DIC. In our study, of the 12 premature infants who died, six had autopsies and of these three showed evidence of thrombosis in large vessels. These three infants had low biologic activity that was less than 50% of the corresponding immunologic levels. Although adults with hereditary thrombophilia may have abnormal thrombosis ( 3 , it is an oversimplification to assume that the low levels of AT-111 and its abnormal function are solely responsible for the occurrence of thromboses in these infants. In support of this, AT-I11 infusions, to neonates with RDS, are not affecting clinical outcome (27) . Other conditions which contribute to thrombus formation in adults also exist in the newborn (5) . Whether the dysfunctional AT-111 reported here is a marker for a pathologic process or is responsible for thrombotic complications in the neonate has not been determined.
